

# Resource Summary Report

Generated by RRID on Aug 5, 2026

## Rules Based Medicine

RRID:SCR\_008575

Type: Tool

### Proper Citation

Rules Based Medicine (RRID:SCR\_008575)

### Resource Information

**URL:** <http://www.rulesbasedmedicine.com/>

**Proper Citation:** Rules Based Medicine (RRID:SCR\_008575)

**Description:** Rules-Based Medicine (RBM) uses proprietary Multi-Analyte Profiling (MAP) technology to make life science research and drug and diagnostic development programs more efficient and effective. Whether measuring hundreds of biomarkers or simply a few, our approach provides reproducible, quantitative immunoassay data from a small sample volume at a cost-effective price. RBM is CLIA certified and supports GLP studies. \* Quality: All immunoassays are validated to clinical laboratory standards. This means complete validation for the clinic, not fit for purpose validation which at RBM means inferior validation. Learn More \* Content: We have the most comprehensive menu of biomarker immunoassays available. \* Small Sample Volumes: Multiplexing provides you with more data using a smaller sample volume. \* Cost Effective: Multiplexing and automation combine to deliver high quality data at reasonable prices. \* Ease of use: Ship us your samples and get results within 2 weeks. Rules-Based Medicine (RBM), the worlds leading multiplexed biomarker testing laboratory, provides comprehensive protein biomarker products and services based on its Multi-Analyte Profiling (MAP) technology platform. RBMs biomarker testing service provides pre-clinical and clinical researchers with reproducible, quantitative, multiplexed immunoassay data for hundreds of proteins in a cost-effective manner, from a small sample volume and from multiple species. Our biomarker testing laboratory is CLIA certified and supports GLP studies. Most diseases and drug effects manifest themselves in abnormal levels of specific biomarkers found in the peripheral blood. By providing multiplexed, quantitative, and reproducible tests for hundreds of biomarkers, RBM enables research that historically was not available due to sample volume requirements and associated costs. Use of our testing services can identify the sources of both the positive and negative effects of drugs during pre-clinical research and clinical trials. Biomarker testing results identify patients most likely to respond to a given therapy and the biochemical reason for that response, making clinical trials more successful and effective. Through its wholly owned subsidiary EDI GmbH, RBM provides Human Organo-Typic (HOT) cell culture systems. These co-culture systems consist of multiple primary cell types grown in a 3-D architecture that closely

mimic particular human organs and are an ideal platform for ex vivo studies of drug safety and efficacy. RBM combines EDIs cell culture systems with its HumanMAP biomarker testing services to provide researchers with an unprecedented view of the physiological and biochemical impact of a new drug compound or consumer product prior to testing in a human subject. RBM also performs custom assay development, participates in co-sponsored research programs, and pursues in-licensing of novel high-value assays.

**Synonyms:** RBM

**Resource Type:** software resource

**Resource Name:** Rules Based Medicine

**Resource ID:** SCR\_008575

**Alternate IDs:** nif-0000-31474

**Record Creation Time:** 20220129T080248+0000

**Record Last Update:** 20260801T190333+0000

---

## Ratings and Alerts

No rating or validation information has been found for Rules Based Medicine.

No alerts have been found for Rules Based Medicine.

---

## Data and Source Information

**Source:** [SciCrunch Registry](#)

---

## Usage and Citation Metrics

We found 26 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [RRID](#) .

Royall DR, et al. (2024) Statin use moderates APOE's and CRP's associations with dementia and is associated with lesser dementia severity in ?4 carriers. Alzheimer's & dementia : the journal of the Alzheimer's Association, 20(3), 1627.

Dratva MA, et al. (2024) Low testosterone levels relate to poorer cognitive function in women in an APOE-?4-dependant manner. Biology of sex differences, 15(1), 45.

Sundermann EE, et al. (2020) Sex differences in Alzheimer's-related Tau biomarkers and a mediating effect of testosterone. Biology of sex differences, 11(1), 33.

Royall DR, et al. (2017) Serum proteins mediate depression's association with dementia. PloS one, 12(6), e0175790.

Royall DR, et al. (2017) Few serum proteins mediate APOE's association with dementia. *PloS one*, 12(3), e0172268.

Royall DR, et al. (2016) Thrombopoietin is associated with  $\tau$ 's intercept, and only in Non-Hispanic Whites. *Alzheimer's & dementia (Amsterdam, Netherlands)*, 3, 35.

Royall DR, et al. (2016) Serum protein mediators of dementia and aging proper. *Aging*, 8(12), 3241.

Barber RC, et al. (2015) Can Genetic Analysis of Putative Blood Alzheimer's Disease Biomarkers Lead to Identification of Susceptibility Loci? *PloS one*, 10(12), e0142360.

Bishnoi RJ, et al. (2015) Serum interleukin (IL)-15 as a biomarker of Alzheimer's disease. *PloS one*, 10(2), e0117282.

Phillips RO, et al. (2014) Combined inflammatory and metabolic defects reflected by reduced serum protein levels in patients with Buruli ulcer disease. *PLoS neglected tropical diseases*, 8(4), e2786.

Kim S, et al. (2013) Influence of genetic variation on plasma protein levels in older adults using a multi-analyte panel. *PloS one*, 8(7), e70269.

Rajagopalan P, et al. (2013) Mapping creatinine- and cystatin C-related white matter brain deficits in the elderly. *Neurobiology of aging*, 34(4), 1221.

Balldin VH, et al. (2012) The Relation between Inflammation and Neuropsychological Test Performance. *International journal of Alzheimer's disease*, 2012, 703871.

Barber RC, et al. (2012) Serum granulocyte colony-stimulating factor and Alzheimer's disease. *Dementia and geriatric cognitive disorders extra*, 2(1), 353.

Jin YF, et al. (2011) Combining experimental and mathematical modeling to reveal mechanisms of macrophage-dependent left ventricular remodeling. *BMC systems biology*, 5, 60.

Gordon CJ, et al. (2011) Serum biomarkers of aging in the Brown Norway rat. *Experimental gerontology*, 46(11), 953.

Craig-Schapiro R, et al. (2011) Multiplexed immunoassay panel identifies novel CSF biomarkers for Alzheimer's disease diagnosis and prognosis. *PloS one*, 6(4), e18850.

Kovalchin J, et al. (2011) Macrophage-specific chemokines induced via innate immunity by amino acid copolymers and their role in EAE. *PloS one*, 6(12), e26274.

O'Bryant SE, et al. (2011) A blood-based screening tool for Alzheimer's disease that spans serum and plasma: findings from TARC and ADNI. *PloS one*, 6(12), e28092.

Ottervald J, et al. (2010) Multiple sclerosis: Identification and clinical evaluation of novel CSF biomarkers. *Journal of proteomics*, 73(6), 1117.